Exact Therapeutics As · OSL:EXTX
Exact Therapeutics As — Investor Presentation (September 2024)
13 slides from Exact Therapeutics As's investor presentation, September 2024
Slide 1: EXACT Therapeutics: Defeating biological barriers in tumours
EXACT Therapeutics Defeating biological barriers in tumours September, 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (the "Presentation") has been prepared by EXACT Therapeutics AS (the "Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’re
Slide 3: Leader in non-invasive, ultrasound mediated oncology therapy
Leader in non-invasive, ultrasound mediated oncology therapy We are building a leading, next generation precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology Focused oncology development strategy: • Oncology platform with clinical proof-of-concept
Slide 4: Pancreatic cancer at a glance
Pancreatic cancer at a glance* Clear unmet medical need • Pancreatic cancer is one of the deadliest cancers • Third most common cancer death • Growing patient population, in particular in younger population groups** • After 5 years, only 12.8% are alive Percentage of Cases by Stage (US) 5-Year Relat
Slide 5: The ACT technology defeats biological barriers that hamper drug delivery
The Acoustic Cluster Therapy (ACT®) technology defeats biological barriers that hamper drug delivery • A noninvasive platform to enable and increase local drug delivery • ACT treatment is given concomitantly with therapeutics Standard of care therapy Microbubble Microdroplet Ultrasound PS101 i.v. in
Slide 6: PS101 – a proprietary ultrasound-activated prodrug
PS101 – a proprietary ultrasound-activated prodrug Commercial scale GMP supply established • PS101 consists of small clusters of gas bubbles and oil droplets • The clusters are free-flowing after injection into the blood, which means they can reach any tissue in the body • Ultrasound exposure conver
Slide 7: A simple and non-invasive treatment process
A simple and non-invasive treatment process ACT achieves therapeutic benefit through a 2-step ultrasound process Step 1: Activation with high frequency (HF) Step 2: Enhancement with low frequency (LF) › › › HF ultrasound is applied Resulting in phase shift LF ultrasound is applied Oscillation of ACT
Slide 8: Strong preclinical evidence across models and drugs
Strong preclinical evidence across models and drugs Oncology Proof-of-concept Mice cancer models, combining different cancer drugs with ACT model Brain Pancreas Breast Colon Prostate Demonstrated 5x increase in ACT + therapy 4x increase in ACT + therapy targeted, complete caused the cancer to comple
Slide 9: ACTIVATE Phase I study – Innovative assessment of anticancer activity
ACTIVATE Phase I study – Innovative assessment of anticancer activity Patients with liver metastases of colorectal origin • All patients receive standard of care treatment Insonation of • One of the liver tumours is treated with ACT one tumour • Intra-patient comparison of tumour response Tumours Su
Slide 10: 10x tumour shrinkage compared to control lesions at interim read in Phase 1 study
10x tumour shrinkage* compared to control lesions at interim read in Phase 1 study on liver metastases • 8 hard-to-treat patients enrolled, with a median of 5 prior lines of therapies (range 3-7) • Up to 4 cycles of ACT (3x IV bolus of PS101 + ultrasound) + FOLFOX (5-fluorouracil [5FU], leucovorin,
Slide 11: ENACT Phase 2 study
ENACT Phase 2 study Locally advanced or borderline resectable pancreatic cancer • Two-armed study (25+25 pts) to investigate the efficacy and safety of ACT® + FOLFIRINOX or ACT® + nab-paclitaxel + gemcitabine treatment in 1L locally advanced/regional or borderline resectable pancreatic cancer patien
Slide 12: EXACT Therapeutics – highlights
EXACT Therapeutics – highlights Unique platform technology Attractive competitive position Ultrasound guided targeted therapeutic First mover (non-invasive, clinical stage) with enhancement using proprietary micro- ultrasound market leader collaboration and bubbles for effective, drug agnostic deliv
Slide 13: ACT® - defeating barriers in solid tumours
Dr Per Walday Caspar Foghsgaard CEO CBO M: +47 917 93 429 M: +47 454 89 233 E: per.walday@exact-tx.com E: caspar.foghsgaard@exact-tx.com ACT® - defeating barriers in solid tumours
EXACT Therapeutics — Investor Presentation (September 2024) on 6ix